Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The announcement provides investors with an update on the analytical and clinical laboratory technology leader’s performance, following a fiscal year 2025 where it generated revenue of $6.95 billion. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day, allowing stakeholders to assess operational trends and financial health.

The conference call is accessible via a listen-only webcast link located in the Events section of Agilent’s Investor Relations website. Management will address questions regarding the quarter’s performance, providing context for the reported figures. This direct engagement channel ensures that investors can receive immediate commentary on key metrics without delay.

Event Details

A recording of the call will also be available on the website for 90 days, ensuring that those unable to attend live can review the discussion later. This extended availability supports transparency and allows for thorough analysis of management’s responses and strategic outlook.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help customers bring great science to life. The company’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to challenging scientific questions. With approximately 18,000 employees worldwide, Agilent continues to support research and development across various industries.

Agilent Technologies Inc. has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The diagnostic enables pathologists to assess PD-L1 expression to identify patients whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy. This development supports informed treatment decisions in a disease where therapeutic options remain limited for many patients.

The certification marks the eighth CE-marked companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006 in the EU. Agilent Technologies announced the approval today, noting that the test allows for assessment in accordance with the approved product labelling. Merck is known as MSD outside the United States and Canada.

Clinical Validation and Partnership

PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma was evaluated using PD-L1 IHC 22C3 pharmDx, Code SK006, in the KEYNOTE-B96/ENGOT-ov65 clinical trial. This trial supported its use as an aid in identifying patients who may be eligible for treatment with pembrolizumab in the platinum-resistant setting. The diagnostic was developed by Agilent in partnership with Merck as a companion diagnostic for KEYTRUDA.

"Expanding access to precision oncology across regions is essential to improving patient outcomes," said Majken Nielsen, vice president and general manager of Agilent’s Clinical Diagnostics Division. "This EU approval builds on our commitment to deliver high-quality companion diagnostics and enables laboratories to support more informed treatment decisions for patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma."

Broader Diagnostic Portfolio

In addition to the new indication, PD-L1 IHC 22C3 pharmDx, Code SK006, is indicated in the EU to help physicians identify patients across several tumor types who may be eligible for treatment with KEYTRUDA, in accordance with the approved product labelling. These tumor types include:

What the Numbers Show

The expansion of the PD-L1 IHC 22C3 pharmDx portfolio to eight CE-marked indications in the EU highlights the broadening utility of Agilent’s diagnostic platform across multiple cancer types. By securing this specific indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, Agilent reinforces its role in the precision oncology ecosystem, directly supporting the deployment of KEYTRUDA in a patient segment with previously limited therapeutic options. Agilent generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.